Stephen Tate, MD
Ophthalmology · Vero Beach, FLNPI 1780736975
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.1%), food and beverage and gifts — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Ivantis, Inc at 51.1% of the total. Reporting peaked in 2019 at $1,401 and has fallen 83.1% since, to $237 in 2025.
Across 55 payments — averaging $44.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ivantis, Inc$1K
- AbbVie$347
- Regeneron Healthcare Solutions, Inc.$160
- Glaukos Corporation$132
- Harrow Eye, LLC$122
- GSK$81
- plus $355 from 12 others
Across 129 payments — averaging $1260.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$141K
- Rxsight Inc$22K
What the payments were for
- Consulting fees$1,25051%
- Speaking & faculty fees$261%
- Food & beverage$1,12746%
- Gifts$452%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ivantis, Inc | 1 | $1,250 |
| AbbVie(2 entities) | 17 | $347 |
| Regeneron Healthcare Solutions, Inc. | 8 | $160 |
| Glaukos Corporation | 2 | $132 |
| Harrow Eye, LLC | 4 | $122 |
| GSK | 4 | $81 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $72 |
| Rxsight Inc | 4 | $70 |
| Aerie Pharmaceuticals, Inc. | 3 | $40 |
| Genentech USA, Inc. | 2 | $34 |
| Dompe US, Inc. | 1 | $23 |
| Biotissue Holdings Inc. | 1 | $22 |
| Amgen | 1 | $21 |
| Sun Pharmaceutical Industries Inc. | 1 | $16 |
| Bausch & Lomb Americas Inc. | 1 | $15 |
| Novartis | 1 | $15 |
| Eyepoint US, Inc. | 1 | $14 |
| Ocular Therapeutix, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus$1,250
How this compares
$2,447 in reported general payments places this provider in the 55th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 167 | $136,256 |
| Cyclosporine | 60 | $32,666 |
| Restasis MultidoseCyclosporine | 28 | $20,093 |
| LumiganBimatoprost | 39 | $16,762 |
| Bromfenac Sodium | 89 | $15,251 |
| Latanoprost | 903 | $12,444 |
| Prednisolone Acetate | 263 | $8,148 |
| IlevroNepafenac | 18 | $7,053 |
| Timolol Maleate | 354 | $5,284 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 241 | $4,463 |
| Difluprednate | 37 | $3,737 |
| Dorzolamide Hcl | 104 | $2,178 |
| Travoprost | 26 | $1,940 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 13 | $1,517 |
| Brimonidine Tartrate | 114 | $1,413 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Restasis Multidose, Lumigan | $347 | $173,112234 claims |
| NovartisIlevro | $15 | $7,05318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Vero Beach
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
- Harold BrooksTallahassee$683K
- Robert WeinstockLargo$605K
- William TrattlerMiami$579K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.